Cancer News and Research

Latest Cancer News and Research

Novelos announces pricing of public offering

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 5,420,800 units at $1.00 per unit for gross proceeds of $5,420,800.

8 Jun 2012

Viewpoints: Bipartisanship on medical device tax; 'Overreach' in contraception fight

Bipartisanship arrived in Washington on Thursday, not that many in the media will hail it. That's because the sweet harmony involved a 270-146 House vote to repeal ObamaCare's 2.3% excise tax on medical devices.

8 Jun 2012

Directly taking accident victims to a trauma centre increases chances of survival

People who are seriously injured in a car accident are more than 30 per cent more likely to survive at least 48 hours if they are taken directly to a trauma centre than those who are taken first to a non-trauma centre, new research has found.

8 Jun 2012

High radon levels in Extremadura

Researchers at the University of Extremadura have measured levels of the radioactive gas radon in 130 workplaces in the Spanish region of Extremadura. The results revealed that 13% of shops, schools, offices, museums and other buildings exceeded EU recommended levels. The record for the highest level of radon is held by a cave in the north of Cáceres in Western Spain.

8 Jun 2012

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Amgen today announced top-line results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis.

8 Jun 2012

What are vitamins?

Most people have heard of vitamin C and its effects upon the body; but how much do you know about other vitamins? How many even are there? And what do they all do?

8 Jun 2012

Large-scale randomized treatment study on adrenocortical cancer

Adrenocortical cancer is an uncommon form of cancer that is often fatal. For the first time, a large-scale randomized treatment study has now been carried out. The study is being published in the prestigious New England Journal of Medicine and constitutes an important and long-awaited platform for continued research.

8 Jun 2012

Concussion victims have unique spatial patterns of brain abnormalities that change over time

Patients vary widely in their response to concussion, but scientists haven't understood why. Now, using a new technique for analyzing data from brain imaging studies, researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that concussion victims have unique spatial patterns of brain abnormalities that change over time

8 Jun 2012

NKI-AVL, Elekta partner to advance cancer research

Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital have signed a strategic alliance to advance cancer research.

From Elekta 8 Jun 2012

Accuray announces outcome data from CyberKnife Prostate SBRT study

Accuray Incorporated, the premier radiation oncology company, announced today that outcome data on intermediate risk prostate cancer patients treated with CyberKnife Prostate SBRT was presented at the American Urological Association Meeting (AUA) 2012 held in Atlanta, Ga.

8 Jun 2012

Second-hand cigarette smoke linked with moderate to severe urinary disorders in children

According to the Environmental Protection Agency, parents are responsible for 90 percent of children's exposure to environmental (second-hand) tobacco smoke. Children with mothers who smoke are at even higher-risk for developing health disorders.

8 Jun 2012

Erivedge drug shows promise against advanced basal cell carcinoma

It's the most common form of skin cancer, but in its advanced stages, basal cell carcinoma has the potential to become disfiguring and life threatening. An international phase 2 study headed by Mayo Clinic led to the recent Food and Drug Administration approval of the first drug of its kind to help advanced basal cell carcinoma patients who have few treatment options.

8 Jun 2012

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

8 Jun 2012

Cardinal Health to launch new technology enhancements at SNM annual meeting

At the Society of Nuclear Medicine's (SNM) 59th Annual Meeting in Miami Beach, Fla., June 9-12, Cardinal Health will introduce new technology enhancements that make it possible for hospital nuclear medicine departments and imaging centers to seamlessly improve data integration and the overall efficiency of their operations.

8 Jun 2012

Nrf2-KEAP1 protein may play a role in diabetic retinopathy

A Wayne State University researcher believes a protein that fails to reach the nucleus of retinal cells may play a role in causing eye disease in people with diabetes.

8 Jun 2012

Tp53 genetic mutation may play an important role in prostate cancer

A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.

8 Jun 2012

Scientists uncover origin of Langerhans cells

Scientists at A*STAR's Singapore Immunology Network (SIgN) uncovered the origin of a group of skin-deep immune cells that act as the first line of defence against harmful germs and skin infections. SIgN scientists discovered that these sentry cells of the skin, called the Langerhans cells (LCs), originate from two distinct embryonic sites - the early yolk sac and the foetal liver.

8 Jun 2012

dSarm/Sarm1 gene promotes axon destruction after injury

Degeneration of the axon and synapse, the slender projection through which neurons transmit electrical impulses to neighboring cells, is a hallmark of some of the most crippling neurodegenerative and brain diseases such as amyotrophic lateral sclerosis (ALS), Huntington's disease and peripheral neuropathy.

8 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012

IRCM researchers make important breakthrough in the field of immunology

A team of researchers at the IRCM led by Dr. Andr- Veillette made an important breakthrough in the field of immunology, which will be published online today by the scientific journal Immunity. The scientists explained a poorly understood molecular mechanism associated with a human immune disorder known as XLP disease or Duncan's syndrome.

8 Jun 2012